Skip to main content
. 2014 Mar 4;9(3):e89789. doi: 10.1371/journal.pone.0089789

Figure 2. Efficacy of tenofovir in Asian-Americans.

Figure 2

(A) Proportion of HBeAg-positive and HBeAg-negative patients with HBV DNA <400 copies/mL by treatment week; (B) Mean change from baseline in HBV DNA in HBeAg-positive and HBeAg-negative patients by treatment week; (C) Fibrotest score categories at baseline and Week 48 in HBeAg-positive and HBeAg-negative patients. HBeAg, hepatitis B ‘e’ antigen; LLOQ, lower limit of quantitation.